AstralBio
Focus: AstralBio is a private Boston-based biotechnology company specializing in machine learning-driven antibody discovery for oncology applications. The company operates as a pre-revenue platform technology player focused on computational drug discovery.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PRIVATE
Open Jobs
0
About AstralBio
AI assessmentNot HiringNo open roles listed right now. Follow AstralBio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
Post-LOE
Post-loss-of-exclusivity generic combination antibiotic—data anomaly suggesting potential portfolio misclassification or legacy asset hold.
Help build intelligence for AstralBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.